Prilenia Announces Plans to Initiate Global Phase III Study of Novel ALS Treatment
Data from prior Phase II study showed signs of pridopidine slowing disease progression in patients with amyotrophic lateral sclerosis.
Antibiotic for Uncomplicated Urinary Tract Infections Granted FDA Priority Review
Pivmecillinam (Pivya) has a clinical cure rate of 95% in uncomplicated urinary tract infections and is recommended as a first-line option for treatment in many countries.
Generative Artificial Intelligence Could Transform Healthcare if Challenges Are Addressed
Critical factors need to be addressed for pharma stakeholders to realize the full potential of generative artificial intelligence.
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel for Severe Sickle Cell Disease
Exagamglogene autotemcel (exa-cel) has shown the potential to be a landmark therapy in preventing episodes of excruciating pain among patients with sickle cell disease.